Johnson & Johnson (NYSE:JNJ) Shares Sold by Litman Gregory Wealth Management LLC

Litman Gregory Wealth Management LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 21.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,818 shares of the company’s stock after selling 500 shares during the quarter. Litman Gregory Wealth Management LLC’s holdings in Johnson & Johnson were worth $295,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Syntegra Private Wealth Group LLC raised its position in Johnson & Johnson by 13.2% in the 3rd quarter. Syntegra Private Wealth Group LLC now owns 2,023 shares of the company’s stock valued at $328,000 after purchasing an additional 236 shares in the last quarter. Rebalance LLC acquired a new stake in Johnson & Johnson in the third quarter valued at approximately $218,000. Spring Capital Management LLC lifted its stake in Johnson & Johnson by 0.8% in the third quarter. Spring Capital Management LLC now owns 40,241 shares of the company’s stock worth $6,268,000 after acquiring an additional 337 shares during the last quarter. Greenleaf Trust grew its holdings in Johnson & Johnson by 7.2% during the 3rd quarter. Greenleaf Trust now owns 98,097 shares of the company’s stock worth $15,898,000 after acquiring an additional 6,628 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI increased its position in shares of Johnson & Johnson by 13.6% in the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 997,912 shares of the company’s stock valued at $161,722,000 after purchasing an additional 119,515 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent analyst reports. Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Sanford C. Bernstein increased their price objective on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. The Goldman Sachs Group decreased their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. TD Cowen dropped their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Finally, Royal Bank of Canada boosted their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $175.93.

Johnson & Johnson Price Performance

Shares of JNJ opened at $165.86 on Thursday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The firm has a 50-day simple moving average of $163.29 and a 200-day simple moving average of $154.92. The company has a market capitalization of $399.17 billion, a price-to-earnings ratio of 10.34, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same period last year, the business posted $2.66 EPS. The company’s revenue was up 5.2% on a year-over-year basis. On average, equities research analysts anticipate that Johnson & Johnson will post 10 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.99%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.